Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

AcelRx Pharmaceuticals to Present at 2018 RBC Capital Markets Global Healthcare Conference

AcelRx Pharmaceuticals,Inc.
Posted on: 16 Feb 18
AcelRx Pharmaceuticals to Present at 2018 RBC Capital Markets Global Healthcare Conference

PR Newswire

REDWOOD CITY, Calif., Feb. 16, 2018

REDWOOD CITY, Calif., Feb. 16, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that Vincent J. Angotti, Chief Executive Officer, will be presenting at the 2018 RBC Capital Markets Global Healthcare Conference.

Details of the event are as follows:

2018 RBC Capital Markets Global Healthcare Conference
Date: Wednesday, February 21, 2018
Location: Lotte New York Palace Hotel, New York
Presentation Time: 8:30am ET, 5:30am PT    

Presentations will be webcast live and can be accessed through the Investors page at www.acelrx.com. For those not available to listen to the live broadcast, a replay will be archived for 90 days and available through the Investors page on www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The company has two product candidates including DSUVIA™ (sufentanil sublingual tablet, 30 mcg), known as DZUVEO outside the United States, with a proposed indication for the treatment of moderate-to-severe acute pain in medically supervised settings, and ZALVISO® (sufentanil sublingual tablet system, SST system, 15 microgram) being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings.

For additional information about AcelRx's clinical programs, please visit www.acelrx.com.

 

View original content with multimedia:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-present-at-2018-rbc-capital-markets-global-healthcare-conference-300599982.html

SOURCE AcelRx Pharmaceuticals, Inc.

PR Newswire
www.prnewswire.com

Last updated on: 16/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.